Related Experiment Video

Updated: May 13, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats

Danielle de Lima Ávila1, Glaucy Rodrigues de Araújo, Maisa Silva

  • 1Núcleo de Pesquisas em Ciências Biológicas-NUPEB, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.

Archives of Medical Research
|March 26, 2013
PubMed
Abstract

Insights

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, reduced oxidative stress and protected pancreatic beta cells in a rat model of type 1 diabetes. Further studies are needed to confirm its therapeutic potential.

Area of Science:

  • Endocrinology
  • Diabetology
  • Oxidative Stress Research

Background:

  • Oxidative stress is implicated in diabetes mellitus pathogenesis.
  • Dipeptidyl peptidase-IV (DPP-IV) inhibitors, like vildagliptin, target incretin hormones (GLP-1, GIP).
  • Incretins offer insulinotropic and cytoprotective effects on pancreatic beta cells.

Purpose of the Study:

  • To evaluate the protective effects of vildagliptin on pancreatic beta cells.
  • To assess vildagliptin's impact in an experimental model of type 1 diabetes induced by streptozotocin (STZ).

Main Methods:

  • Rats with STZ-induced diabetes were treated with vildagliptin (5 and 10 mg/kg) for 4 weeks.
  • Pancreatic oxidative stress markers (TBARS, protein carbonyl) and antioxidant enzymes (SOD, catalase) were measured.
  • Pancreatic histology was analyzed to assess islet and beta cell preservation.

Main Results:

  • Vildagliptin treatment modulated pancreatic stress by reducing TBARS and protein carbonyl levels.
  • Antioxidant enzyme activity (SOD, catalase) was increased by vildagliptin.
  • Histological analysis showed vildagliptin preserved islets and beta cells, particularly at 5 mg/kg.

Conclusions:

  • Vildagliptin ameliorates oxidative stress and protects against pancreatic beta cell destruction in type 1 diabetic rats.
  • The findings suggest vildagliptin's potential in managing type 1 diabetes complications.
  • Further research is required to ascertain the full therapeutic potential of vildagliptin for type 1 diabetes.

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...